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Abstract
Introduction: Neuroinflammation is thought to be important in Alzheimer’s disease pathogenesis. Mast cells are a
key component of the inflammatory network and participate in the regulation of the blood-brain barrier’s
permeability. Masitinib, a selective oral tyrosine kinase inhibitor, effectively inhibits the survival, migration and
activity of mast cells. As the brain is rich in mast cells, the therapeutic potential of masitinib as an adjunct therapy
to standard care was investigated.
Methods: A randomised, placebo-controlled, phase 2 study was performed in patients with mild-to-moderate
Alzheimer’s disease, receiving masitinib as an adjunct to cholinesterase inhibitor and/or memantine. Patients were
randomly assigned to receive masitinib (n = 26) (starting dose of 3 or 6 mg/kg/day) or placebo (n = 8),
administered twice daily for 24 weeks. The primary endpoint was change from baseline in the Alzheimer’s Disease
Assessment Scale - cognitive subscale (ADAS-Cog) to assess cognitive function and the related patient response
rate.
Results: The rate of clinically relevant cognitive decline according to the ADAS-Cog response (increase >4 points)
after 12 and 24 weeks was significantly lower with masitinib adjunctive treatment compared with placebo (6% vs.
50% for both time points; P = 0.040 and P = 0.046, respectively). Moreover, whilst the placebo treatment arm
showed worsening mean ADAS-Cog, Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory, and
Mini-Mental State Examination scores, the masitinib treatment arm reported improvements, with statistical
significance between treatment arms at week 12 and/or week 24 (respectively, P = 0.016 and 0.030; P = 0.035 and
0.128; and P = 0.047 and 0.031). The mean treatment effect according to change in ADAS-Cog score relative to
baseline at weeks 12 and 24 was 6.8 and 7.6, respectively. Adverse events occurred more frequently with masitinib
treatment (65% vs. 38% of patients); however, the majority of events were of mild or moderate intensity and
transitory. Severe adverse events occurred at a similar frequency in the masitinib and placebo arms (15% vs. 13% of
patients, respectively). Masitinib-associated events included gastrointestinal disorders, oedema, and rash.
Conclusions: Masitinib administered as add-on therapy to standard care during 24 weeks was associated with
slower cognitive decline in Alzheimer’s disease, with an acceptable tolerance profile. Masitinib may therefore
represent an innovative avenue of treatment in Alzheimer’s disease. This trial provides evidence that may support a
larger placebo-controlled investigation.
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Alzheimer’s disease (AD) is a degenerative neurological
disorder and the most common cause of dementia and
disability in the older patient [1]. With no known cure
and the currently available treatments only able to tem-
porarily ease symptoms, additional therapeutic options
are required. New therapeutic approaches include mini-
mising accumulation of amyloid-beta (Ab)p e p t i d e si n
the brain [2,3] or targeting cells and signalling pathways
implicated in neuronal destruction associated with neu-
roinflammation [4-6].
Mast cells, which are found on both sides of the
blood-brain barrier (BBB) [7-9], release large amounts of
proinflammatory mediators and therefore play a promi-
nent role in sustaining the inflammatory network of the
central nervous system [10]. Moreover, their ability to
regulate the BBB’s permeability may also be of therapeu-
tic significance; a defective BBB being a common finding
in neuroinflammatory and neurodegenerative diseases,
including AD [8,11-14]. Masitinib mesilate, the investi-
gatory drug of the present study, is a selective tyrosine
kinase inhibitor that targets c-Kit, platelet-derived
growth factor receptors (PDGFR), and, to a lesser
extent, Lyn, Fyn, and the FAK pathway, without inhibit-
ing kinases of known toxicities [15]. By combined tar-
geting of c-Kit and Lyn, masitinib is particularly efficient
in controlling the survival, differentiation, and degranu-
lation of mast cells, and thus indirectly controlling the
array of proinflammatory and vasoactive mediators the
cells can release. Indeed, promising results have been
reported from human clinical trials of masitinib in
inflammatory diseases such as rheumatoid arthritis and
asthma [16,17].
To investigate the hypothesis that masitinib’st a r g e t e d
inhibitory action on mast cells may reduce the symp-
toms of AD, its efficacy and safety was assessed as com-
pared with a placebo. Masitinib was administered orally
as an adjunct therapy to standard care in patients with
mild-to-moderate AD.
Materials and methods
Study design and treatment
A multicentre (12 study centres across France), double-
blind, randomised, placebo-controlled, parallel-group
study of oral masitinib as add-on therapy in mild-to-
moderate AD patients, treated over 24 weeks, was per-
formed. Patients were treated concomitantly with a
stable dose of anti-cholinesterase (donepezil, rivastig-
mine, or galantamine) and/or memantine throughout
the study. To evaluate the optimal starting dose for
masitinib in AD, dose ranging was performed using
masitinib groups of 3 or 6 mg/kg/day. Patients were
randomly allocated to the two masitinib initial dose
groups and placebo group in a 5:5:3 ratio. A centralised
randomisation schedule for packaging and labelling was
generated and held by a third-party service (Cardinal
Systems, Paris, France), and was implemented using an
interactive voice response system. All participants and
study personnel were blinded to treatment allocated
over the study’s duration. For each patient, all efficacy
and safety parameters were recorded on the first day of
treatment (baseline), with patient visits thereafter sched-
uled for weeks 2, 4, 8, 12, and 24. Haematology and bio-
chemistry analyses were performed regularly over the
study period.
Masitinib was provided by AB Science (Paris, France)
in 100 or 200 mg nondivisible coated tablets, to be
administered orally twice daily. For a patient weighing
66 kg to receive the target dose of 6 mg/kg/day, a total
of 396 mg was therefore required, administered as two
200 mg tablets. Composition and dispensing of the
masitinib and placebo treatments were identical except
for the amount of active ingredient contained. Blinded
dose adjustments of 1.5 mg/kg/day were permitted
according to efficacy and safety outcome, with the
dosage being incremented in cases of insufficient
response accompanied by minimal toxicity at weeks 4
and 8 to a maximum dose of 7.5 mg/kg/day (that is, one
additional 100 mg tablet is required for a 66 kg patient
previously receiving 6 mg/kg/day to achieve the theore-
tical dose of 495 mg). Following predetermined criteria,
treatment could be temporarily interrupted and/or the
dosage decreased by 1.5 mg/kg/day in the event of
toxicity.
The present investigation was carried out in accor-
dance with the Declaration of Helsinki and approved by
the national health authorities and a local central ethics
committee (Comité de Protection des Personnes Ile-de-
France II).
Eligibility criteria
Patients aged ≥50 years diagnosed with mild-to-moder-
ate AD (according to Diagnostic and Statistical Manual
of Mental Disorders IV criteria, and to National Insti-
tute of Neurological and Communicative Disorders
and Stroke-Alzheimer’s Disease and Related Disorders
Association criteria), with a baseline Mini-Mental State
Examination (MMSE) score between 12 and 26 and a
baseline Clinical Dementia Rating (CDR) of 1 or 2,
were eligible to participate in the present study.
Patients must have been treated for a minimum of 6
months with stable doses of cholinesterase inhibitors
(donepezil, rivastigmine, or galantamine), and/or mem-
antine for a minimum of 3 months at study entry, with
no dose change foreseen during the study. The pre-
sence of a reliable caregiver was required, with both
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informed consent.
Patients with severe AD or any other cause of demen-
tia were excluded, as were those receiving cognitive
enhancers or disease modifiers other than donepezil,
galantamine, rivastigmine, or memantine. The following
conditions were exclusion criteria: delusions or delirium,
uncontrolled depression, evidence of psychosis and/or
use of antipsychotic drugs, a history of significant psy-
chotic/psychiatric disorders, active infection, treatment
with an investigational agent within 4 weeks of inclu-
sion, or a history of poor compliance.
Efficacy and safety assessment
The primary endpoint was the Alzheimer’s Disease
Assessment Scale - cognitive subscale (ADAS-Cog) to
assess cognitive function. Response was expressed as the
mean difference in ADAS-Cog at week 24 relative to
baseline, and as the proportion of patients achieving a
priori response thresholds at week 24 (defined by a
blinded Data Review Committee prior to unblinding).
Improvement was defined as a decrease ≥4i nA D A S -
Cog score, worsening as an increase ≥4, and any other
change was considered as stable. Secondary endpoints
included: the Alzheimer’s Disease Cooperative Study
Activities of Daily Living Inventory (ADCS-ADL) to
assess self-care; the Clinician’s Interview-Based Impres-
sion of Change-plus caregiver input (CIBIC-Plus) to
assess overall clinical response; the MMSE to evaluate
cognitive function; and the CDR to characterise cogni-
tive and functional performance.
Safety was assessed throughout the study via physical
examinations, vital signs, clinical laboratory evaluations
and monitoring of adverse events (AEs), with all AEs
recorded regardless of causality.
Statistical analysis
Efficacy analyses were performed on the intent-to-treat
and per-protocol populations. The intent-to-treat popu-
lation was defined as all randomised patients, and the
per-protocol population was defined as a subgroup of
the intent-to-treat population that presented no major
protocol deviations. Analysis was conducted using three
possible datasets: (i) imputation of missing values
according to the last observation carried forward
(LOCF) methodology; (ii) an observed cases methodol-
ogy (that is, the absence of data imputation); and (iii)
considering patients with missing data as nonrespon-
ders. Due to circumstances not directly related to the
study (an investigator died), it was not possible to col-
lect week 24 measurements of patients from one study
centre (n = 8; consisting of seven patients from the
masitinib group and one patient from the placebo
group). Week 12 data for this centre were therefore
imputed for week 24 in the observed cases analysis.
Descriptive statistics were used to analyse the safety
population (all patients receiving at least one drug
administration). Quantitative variables were compared
using a nonparametric Wilcoxon rank sum test, and the
Fisher’s exact test was used for comparing categorical
variables. The Cochran-Mantel-Haenzel test was also
used for ordinal variables.
Results
Participant flow
A total of 35 patients were screened between February
2006 and August 2008, of which 34 were randomised:
26 patients into the masitinib group (n =1 2a n dn =1 4
at 3 and 6 mg/kg/day, respectively) and eight patients
into the placebo group (Figure 1). Overall, patient base-
line characteristics were well balanced between treat-
ment arms (Table 1), although the placebo group had a
comparatively higher mean age (78 years vs. 72 years; P
= 0.167) and ADAS-Cog score (25.6 vs. 18.8; P = 0.161).
No protocol deviations were reported as a result of poor
test treatment compliance.
As required by the inclusion criteria, all patients were
receiving a stable dose of a cholinesterase inhibitor, with
eight patients receiving concomitant cholinesterase inhi-
bitors and memantine. Patients were also required to
maintain a stable dose of these drugs during the course
of the study; however, one patient from the masitinib
g r o u pd i s c o n t i n u e dc h o l i n e s t erase inhibitor treatment
(donepezil) on the first day of the study and was with-
drawn on day 29 due to this major protocol deviation.
Minor concomitant treatment protocol deviations were
noted for two patients who did not maintain a stable
dose of cholinesterase inhibitor and/or memantine on
study. One patient in the masitinib group changed type
of medication during the extension phase (donepezil 10
mg modified to memantine 10 mg), and one patient from
the placebo group changed dose of donepezil from 10 to
5 mg after 8 weeks of treatment; both of these patients,
however, were retained for analyses. The mean actual
masitinib dose received was 4.1 ± 1.3 and 6.2 ± 0.6 mg/
kg/day in the theoretical 3 and 6 mg/kg/day groups,
respectively, reflecting that dose increments occurred
more frequently in the initial 3 mg/kg/day group.
In total, 19/34 patients (56%) withdrew before the
planned completion of treatment; 17/26 patients (65%)
from the masitinib group and 2/8 patients (25%) from the
placebo group. If the 8/34 patients (24%) who were with-
drawn due to closure of their treatment centre for circum-
stances unrelated to the study are disregarded, then the
associated patient withdrawal rates become 10/26 patients
(38%) from the masitinib group and 1/8 patient (12.5%)
from the placebo group. Premature withdrawal instigated
by the investigator on grounds of treatment-related AEs
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compared with no patients in the placebo group.
Efficacy
Unless stated otherwise, data from the intent-to-treat
population according to the observed cases dataset
analysis (with LOCF data imputation at week 24 for
those patients withdrawn due to closure of their centre
at week 12) are presented hereafter. A summary of effi-
cacy data at weeks 12 and 24 is presented in Table 2.
Decline of cognitive function, as assessed by the primary
endpoint of ADAS-Cog responder rate, was significantly
9)
Figure 1 Consort diagram. LOCF, last observation carried forward.
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treatment arm after 12 and 24 weeks (50% vs. 6% for both;
P = 0.040 and P = 0.046, respectively). Change in ADAS-
Cog score relative to baseline showed a significant differ-
ence between the masitinib and placebo groups at week
12 (P = 0.016), which was maintained at week 24 (P =
0.030) (Table 2 and Figure 2a). The mean treatment effect
was 6.8 and 7.6, respectively. At both time points an
increase (that is, decline in function) was observed in the
placebo arm’s ADAS-Cog mean scores, whereas the masi-
tinib treatment arm registered mean decreases in scores
(that is, improvement in function).
Table 1 Summary of baseline characteristics
Characteristic Masitinib treatment (n = 26) Placebo (n =8 ) P value
Age (years) 72 ± 12 78 ± 11 0.167
Gender (male/female) 11 (42%)/15 (58%) 2 (25%)/6 (75%) 0.444
Time since diagnosis (years) 1.7 ± 1.1 1.8 ± 0.8 0.320
ADAS-Cog (0 to 70) 18.8 ± 6.7 25.6 ± 12.1 0.161
MMSE (0 to 30) 19.1 ± 3.9 18.0 ± 4.4 0.650
CDR (1/2) 21 (81%)/5 (19%) 6 (75%)/2 (25%) 1.000
ADCS-ADL (0 to 70) 47.1 ± 11.2 45.9 ± 18.0 0.850
Concomitant Alzheimer’s treatment
Cholinesterase inhibitors 26 (100%) 8 (100%) 0.180
Memantine 4 (15%) 2 (25%) 0.610
Data presented as mean ± standard deviation or number (%). ADAS-Cog, Alzheimer’s Disease Assessment Scale - cognitive subscale; ADCS-ADL, Alzheimer’s
Disease Cooperative Study Activities of Daily Living; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination.
Table 2 Summary of efficacy outcomes at weeks 12 and 24
Week 12 Week 24
Treatment arm Masitinib treatment Placebo P value Masitinib treatment Placebo P value
ADAS-Cog
a
Evaluable patients 17 6 16 6
Improvement
b 7 (41%) 1 (17%) 0.369 6 (38%) 1 (17%) 0.616
Worsening
b 1 (6%) 3 (50%) 0.040 1 (6%) 3 (50%) 0.046
Mean absolute change -2.6 ± 3.6 4.2 ± 6.6 0.016 -1.8 ± 6.1 5.8 ± 7.9 0.030
ADCS-ADL
c
Evaluable patients 16 6 15 6
Improvement
d 8 (50%) 0 (0%) 0.051 9 (60%) 1 (17%) 0.149
Worsening
d 5 (31%) 3 (50%) 0.624 4 (27%) 3 (50%) 0.354
Mean absolute change 6.9 ± 10.9 -4.2 ± 6.9 0.035 5.5 ± 15.8 -1.8 ± 7.0 0.128
MMSE
c
Evaluable patients 17 7 16 7
Mean absolute change 0.1 ± 2.5 -2.1 ± 2.5 0.047 -0.1 ± 4.3 -3.3 ± 3.3 0.031
CDR response
e
Evaluable patients 17 7 0.778* 16 7 0.293*
Response 2 (12%) 1 (14%) 3 (19%) 1 (14%)
No change 14 (82%) 5 (71%) 12 (75%) 4 (57%)
Worsening 1 (6%) 1 (14%) 1 (6%) 2 (29%)
CIBIC-Plus
Evaluable patients 17 6 0.292* 16 6 0.474*
Response (1 to 3) 1 (6%) 1 (17%) 2 (13%) 0
No change (4) 14 (82%) 2 (33%) 12 (75%) 5 (83%)
Worsening (5 to 7) 2 (12%) 3 (50%) 2 (13%) 1 (17%)
Summary of efficacy outcomes at weeks 12 and 24 according to observed cases dataset analysis on the intent-to-treat population. Data presented as mean±
standard deviation, or number (%). Week 12 data for closed study centre (n = 8 patients) was imputed using last observation carried forward for week 24. ADAS-
Cog, Alzheimer’s Disease Assessment Scale - cognitive subscale; ADCS-ADL, Alzheimer’s Disease Cooperative Study Activities of Daily Living; CDR, Clinical
Dementia Rating; CIBIC-plus, Clinician’s Interview-Based Impression of Change-plus caregiver input; MMSE, Mini-Mental State Examination.
aNegative change
reflects improvement.
bADAS-Cog response criteria were improvement (decrease ≥4), worsening (increase ≥4).
cPositive change reflects improvement.
dADCS-ADL
response criteria were improvement (increase ≥3), worsening (decrease <0).
eCDR response criteria were positive response (decrease > 0), worsening (increase >
0). *Global P value.
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Figure 2 Summary of efficacy data at weeks 12 and 24. Mean change from baseline to week 24 in (a) Alzheimer’s Disease Assessment Scale
- cognitive subscale (ADAS-Cog), (b) Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) and (c) Mini-Mental
State Examination (MMSE), according to observed cases dataset analysis on the intent-to-treat population. N, number of evaluable patients at
each time point (masitinib-treated versus placebo, respectively).
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ment in daily living activities, defined as an ADCS-ADL
increase ≥3, was higher in the masitinib treatment arm
compared with the placebo arm at weeks 12 and 24;
respectively, 50% versus 0% (P = 0.051) and 60% versus
16.7%, (P = 0.149) (Table 2). The mean change in
ADCS-ADL relative to baseline showed significant
improvement for the masitinib treatment arm compared
with the placebo arm at week 12 (P = 0.035), although
this improvement was no longer statistically significant
at week 24 (P = 0.128) (Figure 2b). At both time points
a mean increase (that is, improvement in function) was
observed for masitinib treatment, while a mean decrease
(that is, decline in function) was observed for placebo
administration.
Assessment of the MMSE score revealed a significant
difference between groups after 12 weeks (P = 0.047)
and 24 weeks of treatment (P = 0.031) (Figure 2c); masi-
tinib-treated patients having steady MMSE scores rela-
tive to baseline compared with negative absolute
changes in the placebo group, representing stability or
decline in cognitive function, respectively. The CIBIC-
plus evaluation showed a worsening score for a lower
proportion of patients in the masitinib treatment arm
compared with the placebo arm at week 12: 2/17
patients (12%) versus 3/6 patients (50%), respectively (P
= 0.089). This difference was no longer apparent at
week 24; however, 2/16 patients (12.5%) did register an
improved response following masitinib treatment com-
pared with none in the placebo group. CDR response
analysis at 24 weeks showed 15/16 (94%) masitinib-trea-
ted patients remained stable or improved relative to
baseline as compared with 5/7 patients (71%) receiving
placebo. Likewise, more patients showed deterioration
under placebo compared with masitinib treatment;
however, no significant differences between treatment
arms were reported (Table 2).
Parallel masitinib-treatment groups at different initial
dose levels were studied to determine the optimal start-
ing dose of masitinib, with dose adjustments possible in
cases of insufficient response. Dose augmentation
occurred in 54% versus 7% of patients in the 3 and 6
mg/kg/day groups, respectively. Furthermore, a higher
rate of cognitive improvement according to decrease in
ADAS-Cog score ≥4 points was observed in the 6 mg/
kg/day masitinib subpopulation (31% vs. 17% at 3 mg/
kg/day). These data suggest that a masitinib starting
dose of 6 mg/kg/day is optimal for future investigations.
Safety
Frequent AEs (with an incidence ≥5%) or any severe
event reported over the 24-week study are presented in
Table 3. Overall, AEs were more common in the masiti-
nib group compared with the placebo group (17/26
patients (65%) versus 3/8 patients (38%), respectively),
with the most frequent toxicities being oedema irrespec-
tive of localisation (31%, including 19% of patients with
peripheral oedema and 15% of patients with eyelid
oedema), gastrointestinal (diarrhoea 23%, nausea 15%,
vomiting 12%), rash (19%), and metabolic or general dis-
orders. The majority of masitinib-associated AEs were of
mild-to-moderate intensity and were transitory. Severe
AEs occurred at a similar frequency in the masitinib
treatment and placebo arms (4/26 patients (15%) and 1/
8 patient (13%), respectively) - the masitinib group
reporting occurrences of rash, anorexia, nausea, asthe-
nia, and transaminase increases (with concomitant mild
neutropaenia and leukopaenia). A total of seven patients
reported at least one nonfatal serious AE, consisting of
1/8 patient (12.5%) from the placebo group and 6/26
Table 3 Number of patients with at least one adverse event (> 5%), according to intensity
Masitinib treatment (n = 26) Placebo (n =8 )
All Severe All Severe
At least one adverse event 17 (65%) 4 (15%) 3 (38%) 1 (13%)
Oedema - all 8 (31%)
Diarrhoea 6 (23%)
Rash - all 5 (19%) 2 (8%)
Anorexia 4 (15%) 2 (8%)
Nausea 4 (15%) 1 (4%)
Vomiting 3 (12%)
Asthenia 3 (12%) 1 (4%)
Bronchitis 2 (8%)
Weight decreased 2 (8%) 1 (13%)
Transaminases increased 2 (8%) 1 (4%)
Arthralgia 2 (8%)
Depression 2 (8%) 1 (13%)
Balance disorder 1 (13%) 1 (13%)
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5/26 patients (19%) were suspected to be treatment
related, with a maximum reaction intensity of severe,
moderate or mild being reported for two patients, two
patients, and one patient, respectively. No deaths
occurred during this study. Seven masitinib patients
(27%) experienced treatment-related AEs that resulted
in treatment discontinuation, including all four patients
with severe AEs and three of the five patients with non-
fatal serious AEs. Comparison of safety between the
masitinib 3 and 6 mg/kg/day groups showed a similar
overall frequency of AEs (69% vs. 62%, respectively);
although there was a slightly elevated occurrence of
severe AEs reported in the 6 mg/kg/day group, three
patients (23%) compared with just one patient (8%) in
the 3 mg/kg/day group.
Discussion
Within the limitations inherent to such relatively small
phase 2 studies, these results suggest that oral masitinib
may have benefits in patients with mild-to-moderate
AD. The mechanisms underlying this response remain
to be elucidated; as orally administered masitinib is unli-
kely to have effectively penetrated the BBB, however, we
may assume its mechanism of action must be indirect,
originating outside the BBB [18]. A growing body of evi-
dence implicates Ab peptides (predominantly Ab42) as
being the main mediator of neurotoxicity in AD [2,3].
Additionally, neuroinflammation is thought to be a
major contributor in the pathogenesis of AD [4-6].
Therapies are therefore being sought that reduce Ab-
peptide accumulation and inflammatory response in the
brain [19]. Moreover, it has been proposed that blood-
borne Ab peptides could represent a substantial and
chronic source of soluble, exogenous Ab peptides [11].
Although plasma levels of Ab peptides are about 20-fold
lower than cerebrospinal fluid levels, altered BBB func-
tion could provide a route for blood-borne Ab peptides
to contribute to AD. The brain is usually protected
from this reservoir of Ab peptides by the BBB; however,
there is evidence suggesting that the BBB is defective in
AD patients [11-14], conceivably allowing an influx of
exogenous Ab peptides and other blood-borne com-
pounds. Therapies to maintain or reinforce the integrity
of the BBB could thus be beneficial in AD.
The possible contribution of mast cells in the physio-
p a t h o l o g yo fA Dr e m a i n sar e l a t i v e l yu n k n o w nf a c t o r
[7,20]. Mast cells reside within the brain, where they are
constitutively active or can be activated by a wide range
of stimuli, including Ab peptides [20]. It has been
shown that mast cells are able to cross the BBB and
their numbers may rapidly increase in response to phy-
siological manipulations [7-9]. Because mast cells release
large amounts of proinflammatory mediators, they play
a prominent role in sustaining the inflammatory net-
work [10]. Additionally, perivascular localised mast cells
secrete numerous vasoactive molecules that regulate
BBB permeability [21,22]. Masitinib is an effective tar-
geted therapy against mast cells, exerting a direct proa-
poptotic, anti-migratory, and anti-activation action [15].
We therefore propose that the positive response
observed from orally administered masitinib is due in
part to its inhibitory action of mast cells. In one possible
scenario, inhibition of mast cell mediators and apoptosis
of mast cells localised at the BBB would effectively
reduce BBB permeability, thereby reinforcing its integ-
rity and stemming the accumulation of exogenous Ab
peptides in the brain with a subsequent decrease in pla-
que formation, inflammatory response and possibly tau
hyperphosphorylation (according to the amyloid hypoth-
esis). Additionally, the influx of proinflammatory mole-
cules released from peripheral mast cells would be
reduced, as well as Ab-induced activation of brain mast
cells, further decreasing neuroinflammation and migra-
tion of mast cells to the brain. Inhibition of mast cells
peripheral to the BBB could therefore impact on the
main pathological features of AD.
In the event that masitinib could pass through the
BBB and accumulate to a sufficiently high therapeutic
concentration - for example, via inflammation-induced
permeability or compromised BBB - then several direct
mechanisms of action are possible. Neuroinflammation
could be reduced through direct inhibition of brain
mast cells and modulation of microglial activity via dis-
ruption of the SCF/c-Kit signalling pathway [15,23].
Damage caused by neurofibrillary tangles or Ab protein
could be reduced via masitinib’s targeting of Fyn or the
FAK pathway, kinases that have been implicated in the
phosphorylation pathway of Tau protein and Ab-
induced cognitive impairment [24-26]. It has also been
shown that activation of PDGFR, Src, and Rac1 could be
relevant for the generation of Ab by neurons, and that
new targets for therapeutic interventions could be found
in this pathway [27]; masitinib’s inhibition of PDGFR
might therefore possibly inhibit Ab generation through
disruption of this pathway. These mechanisms are only
applicable, however, if masitinib crosses into the brain
in sufficient concentration, which was not assessed in
the present study.
T h ec u r r e n ts t u d yh a ss h o w n that masitinib adminis-
tered as an adjunct to standard treatments during 24
weeks may possibly slow the rate of cognitive decline of
AD compared with placebo, as evident from the sus-
tained and statistically significant response in ADAS-
Cog. Significant improvement in cognitive function and
functional capacity compared with placebo was also evi-
dent through the mean change in ADAS-Cog, MMSE,
and ADCS-ADL values relative to baseline - findings
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CIBIC-plus and CDR analyses. Such broad benefits are
desirable in AD, effectively translating into an improved
quality of life. One should note, however, during the 24-
week study period that those patients treated with pla-
cebo in association with cholinesterase inhibitors and/or
memantine experienced an unusually high rate of
decline in their status when compared with reported
studies [28,29]. This observation may reflect a bias
related to the higher age and baseline ADAS-Cog score
of the placebo group, with the possible implication that
this group would experience a faster cognitive decline
resulting in an overestimation of treatment effect. For
progressive diseases such as AD, the use of LOCF analy-
sis is inclined to underestimate cognitive decline; how-
ever, due to the relatively high patient attrition rate,
exasperated by the closure of one centre, it was consid-
ered appropriate to retain the patients from this closed
centre via LOCF analysis for the week 24 analysis. This
again may have tended to overestimation of the treat-
ment effect at week 24, although it should be empha-
sised that significant treatment response was observed at
week 12 for which not data imputation was performed.
Because it is likely that these factors will have resulted
in some degree of overestimation to the observed
response, a number of complementary analyses were
performed. In general, results of the presented ADAS-
Cog analysis were supported by alternative sensitivity
analyses (see Table S1 in Additional file 1). For example,
in the observed cases dataset (without data imputation
for the closed study centre), the mean treatment effect
at week 24 was similar at 7.2 (compared with 7.6),
although the change in ADAS-Cog score relative to
baseline no longer reached statistical significance (P =
0.182) between treatment groups. A higher decline of
cognitive function, as assessed by the ADAS-Cog
responder rate, was also recorded in the placebo arm
compared with the masitinib treatment arm at week 24
(60% vs. 11%, respectively; P = 0.095). Considering ana-
lysis of the intent-to-treat population by last observation
carried forward, the recorded mean treatment effect was
less pronounced at week 24 (3.3 at week 12 and 4.0 at
week 24); however, an increase (that is, decline in func-
tion) was observed in the placebo arm’sA D A S - C o g
mean scores at both time points, whereas the masitinib
treatment arm registered mean decreases (that is,
improvement in function). Additionally, to investigate
the impact of treatment groups not being comparable at
baseline, a multivariate logistic model was constructed
(with adjustment on sex, age and ADAS-Cog score at
b a s e l i n e )t ot e s tt h ee f f e c tof masitinib on worsening
ADAS-Cog score. This model showed that the para-
meters sex (P = 0.754) and ADAS-Cog score (P = 0.974)
had no particular effect, while age (P = 0.232) showed a
nonsignificant effect. Overall, a positive - albeit non-
significant - treatment response was still observed (P =
0.247). Taken together, these complementary analyses
suggest the positive treatment response observed is unli-
kely to be entirely due to baseline or patient withdrawal
effects.
While the safety profile in the present study popula-
tion showed a higher rate of toxicity (approximately 1.7-
fold increase) with masitinib as an adjunct therapy com-
pared with standard (placebo) therapy, the majority of
AEs reported were mild to moderate and transient, with
few severe side effects. The most frequent masitinib-
associated AEs were consistent with the known safety
profile of tyrosine kinase inhibitors - notably oedema,
rash, nausea, vomiting, and diarrhoea, which are gener-
ally considered manageable with symptomatic treat-
ments. A comparison of masitinib’s safety profile in this
study with that of other masitinib phase 2 nononcology
studies shows comparable results, indicating that treat-
ment of this older population with masitinib (median
age 75.5 years vs. 49 years for all other studies) remains
manageable with no indication of additive toxicity when
used in combination with cholinesterase inhibitor and/
or memantine (Table 4). This comparison of masitinib-
related AEs according to population age also revealed
that although the current study population experienced
lower rates of overall and severe AEs compared with the
pooled masitinib population, it had an equivalent rate of
AE-related patient premature withdrawal. This discre-
pancy may reflect an understandably cautious approach
Table 4 Comparison masitinib safety profile in nononcology phase 2 studies
Phase 2 nononcology studies
a Alzheimer study
Controlled Masitinib
(n = 79)
Placebo
(n = 25)
Noncontrolled Masitinib
(n = 137)
Masitinib (n = 26) Placebo
(n =8 )
At least one AE 73 (92%) 19 (76%) 122 (89%) 17 (65%) 3 (38%)
Serious AEs 22 (27%) 3 (12%) 35 (26%) 6 (23%) 1 (13%)
AE (withdrawal)
b 25 (32%) 2 (8%) 44 (32%) 7 (27%) 0
Severe AE 35 (44%) 5 (20%) 49 (36%) 4 (15%) 1 (13%)
Dose reduction
c 8 (10%) 0 (0%) 11 (8%) 4 (15%) 0
AE, adverse event.
aExcluding current Alzheimer study.
bAE leading to patient withdrawal from study.
cAE leading to dose reduction.
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Page 9 of 11to AEs given that this was an older population. The
common misperception that tyrosine kinase inhibitors
are primarily chemotherapeutic agents now being
applied outside their designated field of use may also
have been a contributing factor. On this latter point, it
is a common misnomer to describe masitinib, and simi-
lar tyrosine kinase inhibitors, as a chemotherapeutic
agent because - unlike cytotoxic chemotherapies that
kill all dividing cells, including healthy cells - masitinib
is a targeted therapy. Moreover, depending on which
kinases are targeted, tyrosine kinase inhibitors are
equally well suited for the treatment of nononcology
diseases, as has been previously demonstrated for masi-
tinib in inflammatory and autoimmune diseases with
mast cell involvement, such as rheumatoid arthritis [16],
asthma [17], mastocytosis [30], and atopic dermatitis
[ 3 1 ] ,a sw e l la se x p e r i m e n t a la llergic encephalomyelitis,
an animal model of brain inflammation.
Conclusions
Masitinib, an oral tyrosine kinase inhibitor with high
activity against mast cells, administered as add-on ther-
apy to standard care during 24 weeks showed promising
signs of retarding the rate of cognitive decline of AD
with an acceptable tolerance profile. Masitinib may
therefore represent an innovative avenue of treatment in
AD. Confirmatory phase 3 trials are justified to further
investigate the long-term efficacy and safety of masitinib
as an adjunct therapy with cholinesterase inhibitors and/
or memantine for treatment of mild-to-moderate AD.
Additional material
Additional file 1: Alternative sensitivity analyses on ADAS-Cog
according to the intent-to-treat population. Tabulated data for ADAS-
Cog response rate and ADAS-Cog change relative to baseline according
to the sensitivity analysis approaches of: (1) the observed cases dataset;
2) last observation carried forward; and (3) considering missing data as
nonresponders.
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